Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Navidea Biopharmaceuticals Inc (NY: NAVB )

0.2900 -0.0086 (-2.88%)
Official Closing Price Updated: 8:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 110,419
Open 0.2720
Bid (Size) 0.2760 (3)
Ask (Size) 0.2910 (5)
Prev. Close 0.2986
Today's Range 0.2600 - 0.2979
52wk Range 0.1600 - 1.240
Shares Outstanding 32,364,362
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million. 
Via Benzinga

Performance

YTD
+7.41%
+7.41%
1 Month
-0.17%
-0.17%
3 Month
+47.21%
+47.21%
6 Month
+14.85%
+14.85%
1 Year
-66.67%
-66.67%

More News

Read More
Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Navidea Biopharmaceuticals Files Appeal in CRG Case
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
Via Benzinga
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Kaspien Holdings Is Trading Lower By 13%; Here Are 21 Stocks Moving Premarket
Via Benzinga
Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.